Naturally Occurring Lipid A based Adjuvants
Naturally Occurring Lipid A based Adjuvants
批准号:
8236987
负责人:
Samuel I Miller
金额:
$17.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-01 至 2014-02-28
关键词:
AdjuvantCellsCenters of Research ExcellenceCharacteristicsDevelopmentEmerging Communicable DiseasesEndotoxinsFunding MechanismsGoalsGram-Negative Anaerobic BacteriaHumanImmuneImmune responseImmunityIn VitroLegal patentLipid ALipidsLipopolysaccharidesModelingMusPorphyromonas gingivalisResearchResearch PersonnelStructureTestingToxic effectVaccine AdjuvantVaccinesVirusaluminum sulfatebasebiodefenseimmunogenicimprovedmicrobialmonophosphoryl lipid Amouse modelnovelnovel vaccinespathogenprophylactictumor
中文摘要
需要更有效的疫苗佐剂。历史上明矾是唯一被批准的佐剂
用于人类使用,并且当与全细胞或基于病毒的疫苗一起施用时是有效和安全的。
然而,对细菌致病机制的认识增加导致了新的
针对病原体的疫苗含有更明确的微生物组分选择性组合物,
免疫原性更低。与此同时,辅助研究也随着
单磷酰脂质A(MPL),一种疫苗佐剂,可以安全地增强免疫反应。MPL是
通过有毒细菌脂多糖(LPS)的选择性结构降解而获得,通常被称为
内毒素MPL作为修饰的LPS,保留了其免疫原性特征,同时显著降低了其免疫原性。
毒性作用。然而,从几种厌氧革兰氏阴性菌获得的LPS已经被广泛应用于临床。
显示含有天然存在的低毒性脂质A。最近,我们证明了两个自然的
从牙龈卟啉单胞菌获得的低毒性脂质A可以增强免疫应答,
在小鼠的两种不同肿瘤模型中是有效的疫苗佐剂(牙龈卟啉单胞菌1435/1449
LPS作为免疫调节剂,专利US 2007/0134170 A1)。在这个提议中,我们的假设是:
天然存在的低毒性脂质A代表了一类新的疫苗佐剂。我们将测试
通过从几个物种中分离和表征低毒性脂质A(LT脂质A)来实现这一假设
厌氧革兰氏阴性菌(Aim 1)。然后我们将在体外研究它们的佐剂潜力(目的2)
非特异性免疫(Aim 3)和特异性免疫(Aim 4)小鼠模型。这些研究将确定,
天然存在的LT脂质A代表了一类新的安全有效的疫苗佐剂。
英文摘要
There is a need for more effective vaccine adjuvants. Historically alum has been the only approved adjuvant
for human use and has been effective and safe when administered with whole-cell or virus-based vaccines.
However increased recognition of bacterial pathogenic mechanisms has led to the development of newer
vaccines to pathogens that contain a more defined, microbial component selective composition that often is
less immunogenic. Simultaneously, adjuvant research has advanced with the identification of
monophosphoryl lipid A (MPL), a vaccine adjuvant that can safely boost the immune response. MPL was
obtained by selective structural degradation of toxic bacterial lipopolysaccharide (LPS), often referred to as
endotoxin. MPL, as a modified LPS, retained its immunogenic characteristics while significantly reducing its
toxic effects. However, LPS obtained from several species of anaerobic gram negative bacteria have been
shown to contain a naturally occurring low toxicity lipid A. Recently, we demonstrated that two naturally
occurring low toxicity lipid A's obtained from Porphyromonas gingivalis can boost the immune response and
are effective vaccine adjuvants in two different tumor models in mice (Porphyromonas gingivalis 1435/1449
LPS as an immune modulator, Patent US2007/0134170A1). In this proposal our hypothesis is:
"Naturally occurring low toxicity lipid A's represent a new class of vaccine adjuvants". We will test
this hypothesis by isolating and characterizing low toxicity lipid A's (LT lipid A) from several species of
anaerobic gram negative bacteria (Aim 1). We will then examine their adjuvant potential in in vitro (Aim 2)
and mouse models of non specific (Aim 3) and specific immunity (Aim 4). These studies will determine if
naturally occurring LT lipid A's represent a new class of safe and effective vaccine adjuvants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Salmonella pathogenicity island 2 effector proteins
-
批准号:9526598
-
项目类别:
-
资助金额:$38.76万
-
财政年份:2017
-
负责人:Samuel I Miller
-
依托单位:
Funtion of Uncharacterized Genes of Acinetobacter baumanii
-
批准号:8581005
-
项目类别:
-
资助金额:$144.39万
-
财政年份:2013
-
负责人:Samuel I Miller
-
依托单位:
Administrative Core
-
批准号:8597721
-
项目类别:
-
资助金额:$8.9万
-
财政年份:2013
-
负责人:Samuel I Miller
-
依托单位:
Funtion of Uncharacterized Genes of Acinetobacter baumanii
-
批准号:9282562
-
项目类别:
-
资助金额:$146.37万
-
财政年份:2013
-
负责人:Samuel I Miller
-
依托单位:
Funtion of Uncharacterized Genes of Acinetobacter baumanii
-
批准号:8688145
-
项目类别:
-
资助金额:$161.53万
-
财政年份:2013
-
负责人:Samuel I Miller
-
依托单位:
Funtion of Uncharacterized Genes of Acinetobacter baumanii
-
批准号:8852062
-
项目类别:
-
资助金额:$148.2万
-
财政年份:2013
-
负责人:Samuel I Miller
-
依托单位:
Assigning function of unknown genes of Acinetobacter baumanii by cell envelope
-
批准号:8597718
-
项目类别:
-
资助金额:$35.28万
-
财政年份:2013
-
负责人:Samuel I Miller
-
依托单位:
Diversity of Host Pathogen Interactions
-
批准号:8236991
-
项目类别:
-
资助金额:$39.16万
-
财政年份:2011
-
负责人:Samuel I Miller
-
依托单位:
Administration Core
-
批准号:8236978
-
项目类别:
-
资助金额:$133.79万
-
财政年份:2011
-
负责人:Samuel I Miller
-
依托单位:
ERIN CRC: Molecular Basis of Nontyphoidal Salmonella Emergence
-
批准号:8123203
-
项目类别:
-
资助金额:$114.68万
-
财政年份:2010
-
负责人:Samuel I Miller
-
依托单位:
ERIN CRC: Molecular Basis of Nontyphoidal Salmonella Emergence
-
批准号:7991685
-
项目类别:
-
资助金额:$114.0万
-
财政年份:2010
-
负责人:Samuel I Miller
-
依托单位:
ERIN CRC: Molecular Basis of Nontyphoidal Salmonella Emergence
-
批准号:8511552
-
项目类别:
-
资助金额:$107.38万
-
财政年份:2010
-
负责人:Samuel I Miller
-
依托单位:
ERIN CRC: Molecular Basis of Nontyphoidal Salmonella Emergence
-
批准号:8707321
-
项目类别:
-
资助金额:$114.24万
-
财政年份:2010
-
负责人:Samuel I Miller
-
依托单位:
Genotypic Correlates of Pathogen Diversitiy of NTS in Africa and North America
-
批准号:8026708
-
项目类别:
-
资助金额:$24.72万
-
财政年份:2010
-
负责人:Samuel I Miller
-
依托单位:
ERIN CRC: Molecular Basis of Nontyphoidal Salmonella Emergence
-
批准号:8311842
-
项目类别:
-
资助金额:$114.32万
-
财政年份:2010
-
负责人:Samuel I Miller
-
依托单位:
NW Research Center for Excellence in Biodefense and Emerging Infectious Diseases
-
批准号:7907149
-
项目类别:
-
资助金额:$195.49万
-
财政年份:2009
-
负责人:Samuel I Miller
-
依托单位:
Diversity of Host Pathogen Interactions
-
批准号:7675903
-
项目类别:
-
资助金额:$34.04万
-
财政年份:2009
-
负责人:Samuel I Miller
-
依托单位:
Administration Core
-
批准号:7675839
-
项目类别:
-
资助金额:$120.58万
-
财政年份:2009
-
负责人:Samuel I Miller
-
依托单位:
Administrative Core
-
批准号:7640258
-
项目类别:
-
资助金额:$115.63万
-
财政年份:2008
-
负责人:Samuel I Miller
-
依托单位:
Antibiotic Discovery
-
批准号:7639079
-
项目类别:
-
资助金额:$59.26万
-
财政年份:2008
-
负责人:Samuel I Miller
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: